← Back to patent-cliff list
Mirabegron/Solifenacin Succinate
Tier C — Watch / tradeMirabegron/Solifenacin Succinate
Astellas Pharma Inc.
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：ADRB3, CHRM3
Indications (approved)：Overactive bladder
Regional status
US
Phase III
2014-06-11
EU
Phase III
2014-06-11
China
Phase III
2014-06-11
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Mirabegron/Solifenacin Succinate?
Approved indications include: Overactive bladder.
When does the Mirabegron/Solifenacin Succinate patent expire?
No public expiry year is available for Mirabegron/Solifenacin Succinate yet; this page updates once verified.
How do I get a quote for Mirabegron/Solifenacin Succinate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-12